Tag: Clearmind Medicine - Page 3 - Psychedelic Alpha

Read more about the article Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering

Clearmind Medicine Announces Pricing of US$3.5 Million Public Offering

Post published:April 4, 2023
Post category:Press Release

Read more about the article Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder

Clearmind Medicine Submits IND Application to FDA for its Proprietary CMND-100 Treating Alcohol Use Disorder

Post published:March 16, 2023
Post category:Press Release

Read more about the article Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board

Clearmind Medicine Appoints Professor Henry R. Kranzler, M.D., to Scientific Advisory Board

Post published:March 14, 2023
Post category:Press Release

Read more about the article Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds

Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds

Post published:February 22, 2023
Post category:Press Release

Read more about the article Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US

Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US

Post published:February 15, 2023
Post category:Press Release

Read more about the article Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv

Israel-Based Clearmind Medicine to Present at The OurCrowd Global Investor Summit Sponsored by Greenberg Traurig Tel Aviv

Post published:February 14, 2023
Post category:Press Release

Read more about the article Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Israeli- Based Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity

Post published:February 8, 2023
Post category:Press Release

Read more about the article Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

Israeli Biotech Clearmind Medicine Announces Positive Pre-Clinical Results Treating Major Depression With a Novel Ketamine-Based Compound

Post published:January 31, 2023
Post category:Press Release

Read more about the article Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

Hebrew University’ Yissum and Israeli Biotech Clearmind Medicine’s Psychedelic-Derived Obesity Treatment Presented by Professor Joseph Tam, D.M.D., Ph.D. at Isranalytica 2023

Post published:January 25, 2023
Post category:Press Release

Read more about the article Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum

Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum

Post published:January 20, 2023
Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.